Recent in vitro studies provide evidence for autoantibody-induced suppression of megakaryocytopoiesis, which studies show a reduction in megakaryocyte production and maturation in the presence of immune thrombocytopenia (ITP) plasma. Here, we will present CD34 + cells from healthy umbilical cord blood mononuclear cells cultured in medium containing thrombopoietin, stem cell factor, interleukin-3 and 10% plasma from either ITP patients or healthy subjects. The quantity, quality and apoptosis of megakaryocytes were measured. We observed that most ITP plasma boosted megakaryocyte quantity, but impaired quality, resulting in significantly less polyploidy cells (N≥4) and platelet release. In these megakaryocytes, we found a lower percentage of cell apoptosis, a lower expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and a higher expression of Bcl-xL. Furthermore, there was a decrease of sTRAIL in ITP plasma and in cell culture supernatants of this group when compared with the control group. Our findings suggest that decreased apoptosis of megakaryocytes also contributes to in vitro dysmegakaryocytopoiesis and reduced platelet production. The abnormal expression of sTRAIL in plasma, TRAIL
Introduction
Immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder in which platelets are opsonized by autoantibodies and destroyed by phagocytic cells in the reticuloendothelial system. [1] [2] [3] [4] Although autoantibodies produced by autoreactive B cells against self-antigens, specifically IgG antibodies against GPIIb/IIIa and/or GPIb/IX, are considered to play a crucial role, T-cell mediated immune abnormalities such as Th1 bias, 5, 6 the decreased number or defective function of regulatory T cells 7, 8 and the platelet destruction by cytotoxic T cells (CTL) 9,10 , have been considered equally important in the pathogenesis of ITP. As a result of the accelerated destruction, platelet production is thought to compensatorily increase. However, platelet turnover studies in the 1980s reported that two-thirds of ITP patients showed decreased or normal platelet production, suggesting that impaired platelet production may also contribute to thrombocytopenia.
11
Recent in vitro studies, showing reduced megakaryocyte production and maturation in the presence of autoantibodies against platelet glycoproteins in ITP plasma, have provided evidence for autoantibody-induced suppression of megakaryocytopoiesis. 12, 13 However; reduced platelets cannot be ascribed to decreased megakaryocyte production in ITP patients with normal or increased bone marrow magakaryocytes.
It has been known that platelets are formed from mature megakaryocytes and arise from the development of long and thin cytoplasmic extensions called proplatelets. [14] [15] [16] Several reports indicate a close relationship among apoptosis, megakaryocyte maturation, and platelet release. Zauli et al 17 found that the onset of megakaryocyte apoptosis coincides with the maximum in the high ploidy megakaryocyte fraction and the number of platelets released in the culture. De Botton et al 18 elegantly provided evidence that proplatelet formation was a consequence of local caspase activation during megakaryocyte differentiation. Therefore, we suppose abnormal megakaryocyte apoptosis may be responsible for persistent thrombocytopenia in ITP.
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In the present study, we observed that most ITP plasma inhibited megakaryocyte apoptosis, boosted megakaryocyte mass and depressed platelet production in vitro, suggesting a possible role of megakaryocyte apoptosis in the pathogenesis of ITP.
Materials and methods

Patients and controls
Whole blood was collected from 49 patients (28 females and 21 males) with chronic ITP, all of whom did not undergo any form of therapy for at least three weeks prior to blood sampling ( Table 1 ). The diagnosis in all patients, based on the criteria for chronic ITP as previously described, 19 exhibited isolated thrombocytopenia for more than 12 months, normal or increased bone marrow megakaryocytes, normal spleen size, and no secondary immune or nonimmune abnormality that could account for the thrombocytopenia. Patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS) were excluded from this study, as were pregnant patients or those with concomitant human immunodeficiency or hepatitis C virus 
Plasma preparation
Plasma samples were obtained from ethylenediaminetetraacetic acid (EDTA) anticoagulated blood by centrifugation at 3000 g for 30 min at 20°C to remove platelets, and stored at -80°C prior to use.
IgG purification
IgG antibody was purified from plasma by affinity chromatography using 4HiTrap
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Protein A HP column which was operated with AKTA explorer 100 chromatography system (Amersham Co., Sweden ) according to the manufacturer's instructions. The
IgG concentration was adjusted to 1.2 mg/ml. The final IgG preparations were dialyzed overnight with culture medium.
Adsorption of autoantibodies from ITP plasma
ITP patient plasma (0.5 ml) was mixed with the washed control platelets (1×10 9 /ml plasma) and incubated at 4°C for 1 hour. After centrifugation at 3000g for 5 minutes, the supernatant plasma was again adsorbed with fresh platelets at 4°C for 1 to 1.5 hours. The adsorbed plasma was then analyzed by modified monoclonal antibody specific immobilization of platelet antigens (MAIPA) for the presence of autoantibodies as previously described in detail by Hou et al. 20 Megakaryocyte culture
CD34
+ cells were purified from healthy umbilical cord blood mononuclear cells To measure ploidy distribution, the megakaryocytes were identified after labeled with PEcy5-conjugated CD41a mAb and incubated with 500μl propidium iodide (PI, BD ParMingen, San Diego, CA, USA) containing RNase. CD41a + cells were gated and ploidy distribution was assessed by the intensity of the PI fluorescence.
Detection of platelets produced in culture was performed as previously described. 21 In brief; cultured cells were centrifuged at 350g for 15 minutes and incubated with PEcy5-conjugated CD41a mAb. After incubation, each sample was diluted to 300µl and collected at median rate for 50 seconds by flow cytometry. An analytical gate was determined according to scatter properties of normal blood platelets treated similarly using a log scale for FSC and SSC which excluded large contaminating cells (megakaryocytes) and small debris or microparticles.
Megakaryocyte apoptosis was measured using the Annexin V-FITC Apoptosis We also measured the expression of TRAIL on the surface of produced platelets.
Cultured cells were centrifuged at 350g for 15 minutes and incubated with PEcy5-conjugated CD41a mAb and PE-conjugated mouse anti-human TRAIL. After incubation, each sample was diluted to 300µl and collected at median rate for 50 seconds by flow cytometry as described above.
ELISA for TPO, IL-11, sFas and sTRAIL in plasma
The levels of plasma TPO and IL-11 in controls and patients were measured by sandwich ELISA kits (R&D, Oxon, United Kingdom) according to the manufacturer's 
Statistical analysis
All data is presented as mean ± standard deviation (SD). Differences among four groups were assessed using analysis of variance (ANOVA) and differences among four groups at different measuring time were assessed using repeated measures of ANOVA analysis. Because some of the data had heterogeneity of variance, comparison between these numbers was analyzed by Kruskal-Wallis test. P value less than 0.05 was considered statistically significant. Statistical analysis was performed by the SPSS 13.0 (SPSS Inc., Chicago, USA) statistical software programs.
Results
Effects of ITP plasma on megakaryocyte production, maturation and platelet release
As shown in Figure 1A , ITP patients can be divided into three groups according to the effect that their plasma had on megakaryocyte production after 15 days co-culture. To rule out the possibility that TPO and IL-11, the known positive regulators of megakaryopoiesis, [22] [23] [24] might be elevated in ITP plasma from group A compared with controls and other groups, we assayed the plasma levels of TPO and IL-11 by ELISA.
Consistent with previous reports, 25-27 TPO levels in plasma did not differ significantly Figure 1C ).
The megakaryocyte polyploidy and platelet counts in group A and group B were significantly lower than those in controls (P<0.0001).
Inhibited apoptosis and overexpressed Bcl-xL in megakaryocytes cultured with group A ITP plasma
As shown in Figure 1D , reduced megakaryocyte apoptosis was observed in group A was relatively stable and showed no significant difference in megakaryocytes among the four groups.
Effects of patient IgG on megakaryocyte yield, maturation, apoptosis and platelet release
To evaluate the role of autoantibody on the quantity and quality of megakaryocytes, we studied the effects of patient and control IgG on megakaryocyte production, ploidy distribution, platelet release and megakaryocyte apoptosis.
A significant reduction in megakaryocyte production, ploidy distribution and (Figure 2A, 2C in megakaryocytes at day 6, 10, 14 of the culturing process. As a result, at day 6, TRAIL, caspase-3 and caspase-8 expression in megakaryocytes did not differ significantly among the four groups. While at day 10 and 14, the expression of TRAIL, caspase-3 and caspase-8 in group A were remarkably lower than that of controls, but there was no significant difference amongst group B, group C and the controls ( Figure   4B -D). On the other hand, the decreased expression of TRAIL, caspase-3 and caspase-8 in group A were consistent with inhibited megakaryocyte apoptosis and decreased platelet production at day 10 and 14 of the culture process. However, the expression of Fas and FasL were low and showed no significant difference on the surface of megakaryocytes among the four group cultures at any detecting points. The expression of TRAIL-R2 on megakaryoctes and the expression of TRAIL on produced platelets were relatively stable and showed no significant difference among the four groups at any detecting points.
Decreased sTRAIL expression in plasma and cell culture supernatants of group A
We measured sFas and sTRAIL in plasma and cell culture supernatants to see if these two factors contributed to abnormal megakaryocyte apoptosis. Figure 5A show the plasma sFas levels of different groups. Figure 5D ). sTRAIL levels in plasma and cell culture supernatants showed no remarkable differences among group B, group C and controls at any detecting points.
Discussion
In the early 1980s, studies of autologous platelet survival showed that in the majority of ITP patients, platelet turnover was either reduced or normal. It would be expected that platelet destruction was not the sole pathogenic mechanism, and impaired platelet production might also contribute to persistent thrombocytopenia. Chang et al 12 reported that production of megakaryocytes was significantly reduced in the presence of ITP plasma with detectable antiplatelet GPIb autoantibodies. McMillan et al 13 recently
documented that ITP plasma with detectable anti-GPIIb/IIIa, anti-GPIb or both not only reduced the yield of megakaryocytes, but also suppressed megakaryocyte maturation.
Our present results in patients with chronic ITP are similar, in some way, to previous studies mentioned above. We showed that some (group B) ITP plasma suppressed megakaryocytopoiesis and autoantibody from some ITP plasma exerted suppression on megakaryocyte production, maturation and platelet release.
Autoantibody adsorption further confirmed that the autoantibody may be partly responsible for the reduced yields of megakaryocytes and platelets. Several possible mechanisms may contribute to the suppression of megakaryocyte production by autoantibodies. First, megakaryocytes express GPIIb/IIIa or GPIb/IX on their surfaces Moreover, as with two important cyclins in megakaryocyte development and high ploidy formation, 32 the absence of cyclin D3 during the whole culture and low expression of cyclin B1 at early stage may have been the mechanism by which patient IgG inhibited megakaryocyte polyploidization. As a result, IgG in ITP plasma destructed megakaryocytes and affected megakaryocyte polyploidy, leading to less megakaryocyte ploidy and platelet release. However, even when cultured with autoantibody-adsorbed plasma, more megakaryocytes were not reasonably accompanied with more polyploidy cells and platelet production, indicating that autoantibody was not the sole factor in impairing megakaryocyte maturation and platelet production.
In the present work, we were surprised to find that the group with the most ITP plasma (group A) boosted megakaryocyte counts, while impairing megakaryocyte maturation and its ability to produce platelets. shown that the Fas/FasL system may accelerate megakaryocytic apoptosis and platelet release, 35 Fas and FasL are mainly expressed on T and B lymphocytes, inducing cellular apoptosis disorder associated with cellular and humoral immune reaction.
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Yoshimura C et al 37 reported that there were two groups of ITP patients, one with elevated levels of sFas/sFasL in their plasma and the other with normal levels, suggesting that the pathogenesis of some ITP patients might include an alteration of the Fas/FasL pathway. In our study, the sFas levels in cell culture supernatant of group A were significantly lower than those in control supernatants at day 6 and 10, which was consistent with the data from Yoshimura. However, no difference was found at day 14, the surface expressions of Fas and FasL on megakaryocytes were low in both ITP patients and controls, and sFas levels in plasma showed no difference between ITP patients and controls. These findings indicate that Fas/FasL interaction is important in lymphocyte apoptosis, but plays little role in decreased megakaryocyte apoptosis in ITP patients. The sFas in plasma seems not to be the factor contributing to decreased platelet production in ITP.
Several studies indicate that TRAIL is involved in the pathogenesis of some autoimmune diseases including systemic lupus erythematosus (SLE) ， Sjogren syndrome and autoimmune thyroid diseases. [38] [39] [40] Previous studies [41] [42] [43] show that TRAIL can promote the maturation and apoptosis of megakaryocytes. Human megakaryocytes cultured in vitro express TRAIL and TRAIL-R2 on their surfaces. Similarly, platelets also express TRAIL, which may be obtained from megakaryocytes. We found that TRAIL expression on megakaryocytes and sTRAIL concentrations in plasma and cell culture supernatants of group A patients were prominently decreased when compared with the other three groups. Therefore, decreased sTRAIL might be a contributing factor to impaired megakaryocyte apoptosis. As we expected, both the expression of caspase-8 and caspase-3 decreased in group A megakaryocytes. We inferred that decreased TRAIL expression may have led to less caspase-8 and caspase-3 activation, thus triggering less megakaryocyte apoptosis. In addition, although TRAIL expression on the surface of platelets was almost equal, platelets produced in group A were much lower than controls. In a word, the total TRAIL expression on the platelet surface of group A might be in a much lower level, which may enhance the role of TRAIL in impaired megakaryocyte apoptosis through the TRAIL/TRAIL-R2 pathway. Recently, which is a little different from the results of our study. However, severe LPD is due to maximal resistance of lymphocytes to activation-induced cell death (AICD) and dysregulated lymphocyte homeostasis resulted in the production of anti-platelet IgM and IgG causing thrombocytopenia. As a result, spontaneous thrombocytopenia in these mice is secondary to LPD. This is somewhat different from the mechanism of primary immune thrombocytopenia.
Recent studies showed that Bcl-xL is up-regulated during megakaryocyte differentiation but is absent from senescent megakaryocytes. 45, 46 Over expression of Bcl-xL could decrease platelet formation. 47 Therefore, Bcl-xL, as an anti-apoptosis factor, should play a role in megakaryocyte differentiation and apoptosis, as well as in platelet formation. Lei Zhang et al 48 discovered that Bcl-xL is down-regulated early during in vitro differentiation of megakaryocytes from essential thrombocythemia (ET)
patients, leading to overproduction of megakaryocytes and platelets. In the current research, we found that megakaryocytes in group A had higher Bcl-xL expression when compared with other groups on day 8, prior to the peak day of high ploidy For All data were presented as mean ± SD. control supernatants at day 6 and 10 (P<0.0001). At day 14, sFas levels in cell culture supernatants did not differ significantly between ITP patients in group A and controls and there were no remarkable differences among group A, group B and group C at any detecting time. (C) Plasma sTRAIL concentration was deceased in group A ITP patients compared to healthy controls (P<0.0001). There were no remarkable differences among group B, group C and controls. (D) At day 6, 10 and 14, sTRAIL concentration in cell culture supernatants of group A were remarkably lower than those in controls (P<0.0001). There were no remarkable differences among group B, group C and controls at any detecting time.
